Stifel Financial
XFOR icon

Stifel Financial’s X4 Pharmaceuticals XFOR Stock Holding History

Stifel Financial’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90K Buy
21,789
+1,293
+6% +$4.84K ﹤0.01% 3544
2025
Q4 		$82K Buy
+20,496
New +$74.5K ﹤0.01% 3498
2025
Q2 		– Sell
-2,518
Closed -$17.9K – 3587
2025
Q1 		$17.9K Sell
2,518
-2
-0.1% -$28 ﹤0.01% 3396
2024
Q4 		$55.5K Sell
2,520
-1,562
-38% -$24.9K ﹤0.01% 3306
2024
Q3 		$82K Sell
4,082
-1,394
-25% -$29.1K ﹤0.01% 3266
2024
Q2 		$95.3K Buy
5,476
+2,602
+91% +$85.1K ﹤0.01% 3221
2024
Q1 		$120K Sell
2,874
-141
-5% -$3.92K ﹤0.01% 3175
2023
Q4 		$75.8K Buy
3,015
+339
+13% +$8.24K ﹤0.01% 3189
2023
Q3 		$87.5K Sell
2,676
-35
-1% -$1.53K ﹤0.01% 3131
2023
Q2 		$158K Sell
2,711
-406
-13% -$20.9K ﹤0.01% 3094
2023
Q1 		$81.3K Buy
3,117
+384
+14% +$11.3K ﹤0.01% 3203
2022
Q4 		$81.4K Buy
2,733
+489
+22% +$23.2K ﹤0.01% 3156
2022
Q3 		$115K Sell
2,244
-5
-0.2% -$173 ﹤0.01% 3090
2022
Q2 		$65K Sell
2,249
-71
-3% -$2.7K ﹤0.01% 3206
2022
Q1 		$122K Buy
+2,320
New +$133K ﹤0.01% 3233

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Stifel Financial's XFOR Position: Q1 2026 in Review

Stifel Financial increased its X4 Pharmaceuticals (XFOR) stake by 6.3% in Q1 2026, buying an estimated $4.84K and bringing the position to 21,789 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #3544.

Stifel Financial first reported a position in XFOR in Q1 2022 and has held it in 15 quarters since. The position peaked at $158K in Q2 2023. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Stifel Financial held 21,789 shares of X4 Pharmaceuticals worth $90K as of Q1 2026.
  • Stifel Financial bought 1,293 X4 Pharmaceuticals shares in Q1 2026, an estimated $4.84K.
  • X4 Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #3544 holding.
  • Stifel Financial first reported a position in X4 Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • Stifel Financial's X4 Pharmaceuticals position peaked at $158K in Q2 2023.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.